Physician profile
Michael S Digby
NPI 1871758938
$5,359.49
in general payments reported to CMS, 2019-2025
28 companies · $710 in 2025
The $710 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $452 · 2021: $988 · 2022: $1,066 · 2023: $965 · 2024: $921 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,301.67 | 2019-2025 | |
| Janssen Biotech, INC. | $551.35 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| E.R. Squibb & Sons, L.L.C. | $503.64 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $487.06 | 2019-2025 | Taltz, Ebglyss |
| Abbvie INC. | $411.15 | 2020-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $383.86 | 2019-2025 | Dupixent |
| Genzyme Corporation | $304.72 | 2021-2024 | |
| Amgen INC. | $248.13 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $245.30 | 2019-2025 | |
| Galderma Laboratories, L.P. | $172.55 | 2022-2025 | Nemluvio |
| Ucb, INC. | $143.70 | 2022-2025 | Bimzelx, Briviact |
| Boston Scientific Corporation | $109.87 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Sun Pharmaceutical Industries INC. | $84.30 | 2020-2024 | Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $59.20 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $32.41 | 2023 | Adbry |
| Mimedx Group, INC. | $29.59 | 2024 | |
| Mallinckrodt Hospital Products INC. | $24.42 | 2025 | Acthar |
| Genentech USA, INC. | $23.53 | 2023 | Erivedge |
| Janssen Scientific Affairs, LLC | $20.14 | 2021 | |
| Botanix Sb INC | $19.72 | 2025 | Sofdra |
| Biofrontera INC. | $19.44 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.40 | 2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $15.03 | 2023-2024 | |
| Smith+Nephew, INC. | $14.96 | 2023 | Collagenase Santyl |
| Verrica Pharmaceuticals INC. | $14.90 | 2023 | Ycanth |
| Organon LLC | $14.40 | 2025 | Vtama |
| Dermavant Sciences, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Digby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.